Galmed Pharmaceuticals Future Growth
Future criteria checks 0/6
Galmed Pharmaceuticals's earnings are forecast to decline at 26.1% per annum. EPS is expected to grow by 10.5% per annum.
Key information
-26.1%
Earnings growth rate
10.5%
EPS growth rate
Biotechs earnings growth | 21.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Nov 2023 |
Recent future growth updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -17 | N/A | N/A | 1 |
12/31/2025 | N/A | -14 | N/A | N/A | 1 |
12/31/2024 | N/A | -11 | N/A | N/A | 1 |
12/31/2023 | N/A | -7 | -6 | -6 | N/A |
9/30/2023 | N/A | -8 | -9 | -9 | N/A |
6/30/2023 | N/A | -11 | -10 | -10 | N/A |
3/31/2023 | N/A | -14 | -15 | -15 | N/A |
12/31/2022 | N/A | -18 | -19 | -19 | N/A |
9/30/2022 | N/A | -23 | -21 | -21 | N/A |
6/30/2022 | N/A | -25 | -27 | -27 | N/A |
3/31/2022 | N/A | -30 | -29 | -29 | N/A |
12/31/2021 | N/A | -32 | -33 | -33 | N/A |
9/30/2021 | N/A | -35 | -34 | -34 | N/A |
6/30/2021 | N/A | -34 | -30 | -30 | N/A |
3/31/2021 | N/A | -32 | -29 | -29 | N/A |
12/31/2020 | N/A | -29 | -26 | -26 | N/A |
9/30/2020 | N/A | -27 | -23 | -23 | N/A |
6/30/2020 | N/A | -24 | -21 | -21 | N/A |
3/31/2020 | N/A | -23 | -18 | -18 | N/A |
12/31/2019 | N/A | -20 | -15 | -15 | N/A |
9/30/2019 | N/A | -16 | -13 | -13 | N/A |
6/30/2019 | 2 | -12 | -11 | -11 | N/A |
3/31/2019 | 2 | -11 | -9 | -9 | N/A |
12/31/2018 | 2 | -10 | -9 | -9 | N/A |
9/30/2018 | 2 | -10 | -9 | -9 | N/A |
6/30/2018 | 1 | -12 | -10 | -10 | N/A |
3/31/2018 | 1 | -12 | -12 | -12 | N/A |
12/31/2017 | 1 | -12 | -12 | -12 | N/A |
9/30/2017 | 1 | -13 | N/A | -12 | N/A |
6/30/2017 | 1 | -15 | N/A | -13 | N/A |
3/31/2017 | 1 | -16 | N/A | -13 | N/A |
12/31/2016 | 0 | -17 | N/A | -12 | N/A |
9/30/2016 | 0 | -15 | N/A | -12 | N/A |
6/30/2016 | N/A | -14 | N/A | -11 | N/A |
3/31/2016 | N/A | -12 | N/A | -9 | N/A |
12/31/2015 | N/A | -11 | N/A | -8 | N/A |
9/30/2015 | N/A | -9 | N/A | -9 | N/A |
6/30/2015 | N/A | -10 | N/A | -9 | N/A |
3/31/2015 | N/A | -9 | N/A | -9 | N/A |
12/31/2014 | N/A | -9 | N/A | -9 | N/A |
9/30/2014 | N/A | -22 | N/A | -8 | N/A |
6/30/2014 | N/A | -20 | N/A | -6 | N/A |
3/31/2014 | N/A | -19 | N/A | -4 | N/A |
12/31/2013 | N/A | -17 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GLMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GLMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if GLMD's revenue is forecast to grow faster than the US market.
High Growth Revenue: GLMD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GLMD's Return on Equity is forecast to be high in 3 years time